

Benjamin Chaigne

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/214524/publications.pdf>

Version: 2024-02-01

50
papers

1,154
citations

471477

17
h-index

434170

31
g-index

50
all docs

50
docs citations

50
times ranked

2049
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e419-e426.	3.9	211
2	Pulmonary manifestations of Sjögren's syndrome. <i>European Respiratory Review</i> , 2016, 25, 110-123.	7.1	206
3	Mechanisms of action of intravenous immunoglobulin. <i>Transfusion and Apheresis Science</i> , 2017, 56, 45-49.	1.0	78
4	Scleroderma Peripheral B Lymphocytes Secrete Interleukin-6 and Transforming Growth Factor β^2 and Activate Fibroblasts. <i>Arthritis and Rheumatology</i> , 2017, 69, 1078-1089.	5.6	59
5	Impact of disease activity on health-related quality of life in systemic lupus erythematosus – a cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS). <i>BMC Immunology</i> , 2017, 18, 17.	2.2	42
6	Patients' views and needs about systemic sclerosis and its management: a qualitative interview study. <i>BMC Musculoskeletal Disorders</i> , 2017, 18, 230.	1.9	42
7	Immunogenicity of Anti-HLA Antibodies in Pancreas and Islet Transplantation. <i>Cell Transplantation</i> , 2016, 25, 2041-2050.	2.5	38
8	French recommendations for the management of systemic sclerosis. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 322.	2.7	37
9	Levamisole-induced vasculopathy: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 921-926.	3.4	35
10	The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET. <i>Nature Reviews Rheumatology</i> , 2021, 17, 177-184.	8.0	35
11	Mixed connective tissue disease: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000783.	3.8	30
12	Changes in mental health symptoms from pre-COVID-19 to COVID-19 among participants with systemic sclerosis from four countries: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study. <i>Journal of Psychosomatic Research</i> , 2020, 139, 110262.	2.6	25
13	Dividing the Janus vasculitis? Pathophysiology of eosinophilic granulomatosis with polyangiitis. <i>Autoimmunity Reviews</i> , 2016, 15, 139-145.	5.8	24
14	Corticosteroid-sparing benefit of intravenous immunoglobulin in systemic sclerosis-associated myopathy: A comparative study in 52 patients. <i>Autoimmunity Reviews</i> , 2020, 19, 102431.	5.8	24
15	Primary Sjögren's syndrome and occupational risk factors: A case-control study. <i>Journal of Autoimmunity</i> , 2015, 60, 80-85.	6.5	22
16	Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients. <i>Journal of Psychosomatic Research</i> , 2020, 135, 110132.	2.6	21
17	Role of B-Cell in the Pathogenesis of Systemic Sclerosis. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	20
18	Monoclonal antibodies in excess: A simple way to avoid immunogenicity in patients?. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 814-816.	2.9	19

#	ARTICLE	IF	CITATIONS
19	Differential impact of systemic lupus erythematosus and rheumatoid arthritis on health-related quality of life. <i>Quality of Life Research</i> , 2017, 26, 1767-1775.	3.1	16
20	Pathophysiology of systemic sclerosis. <i>Presse Medicale</i> , 2021, 50, 104087.	1.9	14
21	Vasculitis for the internist: focus on ANCA-associated vasculitis. <i>Internal and Emergency Medicine</i> , 2017, 12, 577-585.	2.0	13
22	Autoantibodies versus Skin Fibrosis Extent in Systemic Sclerosis: A Case-Control Study of Inverted Phenotypes. <i>Diagnostics</i> , 2022, 12, 1067.	2.6	12
23	Mycophenolate mofetil in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis: a prospective pharmacokinetics and clinical study. <i>Clinical and Experimental Immunology</i> , 2014, 176, 172-179.	2.6	10
24	Treatment of systemic sclerosis. <i>Presse Medicale</i> , 2021, 50, 104088.	1.9	10
25	Anti-“programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study. <i>European Journal of Cancer</i> , 2022, 160, 134-139.	2.8	10
26	Extra-haematological manifestations related to human parvovirus B19 infection: retrospective study in 25 adults. <i>BMC Infectious Diseases</i> , 2018, 18, 302.	2.9	9
27	Ophthalmic involvement of chronic lymphocytic leukemia: A systematic review of 123 cases. <i>Survey of Ophthalmology</i> , 2021, 66, 124-131.	4.0	9
28	Factors associated with fears due to COVID-19: A Scleroderma Patient-centered Intervention Network (SPIN) COVID-19 cohort study. <i>Journal of Psychosomatic Research</i> , 2021, 140, 110314.	2.6	9
29	Stevens-Johnson Syndrome Induced by Masitinib. <i>Acta Dermato-Venereologica</i> , 2012, 92, 210-212.	1.3	6
30	Skewed peripheral B- and T-cell compartments in patients with ANCA-associated vasculitis. <i>Rheumatology</i> , 2021, 60, 2157-2168.	1.9	6
31	Drug-induced eosinophilic fasciitis: A dual pharmacovigilance analysis. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 1372-1375.	1.2	6
32	18 FDG PET/CT Contribution in Occult Giant-Cell Arteritis. <i>Journal of Clinical Rheumatology</i> , 2012, 18, 104-105.	0.9	6
33	Melanoma lymph node metastasis occurring simultaneously with multifocal sarcoidosis affecting lymph nodes and the lung: a diagnostic pitfall. <i>European Journal of Dermatology</i> , 2011, 21, 798-799.	0.6	6
34	Theranostic of biopharmaceuticals. , 2017, 175, 67-74.		5
35	Proteomic Analysis of Human Scleroderma Fibroblasts Response to Transforming Growth Factor-“γ. <i>Proteomics - Clinical Applications</i> , 2019, 13, 1800069.	1.6	5
36	Trunk involvement and peau d'orange aspect are poor prognostic factors in eosinophilic fasciitis (Shulman disease): A multicenter retrospective study of 119 patients. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 160-163.	1.2	5

#	ARTICLE	IF	CITATIONS
37	High D-dimer plasma concentration in systemic sclerosis patients: Prevalence and association with vascular complications. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 178-186.	1.7	5
38	Unsolved questions and concerns about treatment of anti-neutrophil cytoplasm antibody-associated vasculitides. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S121-8.	0.8	5
39	The Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program: protocol for a two-arm parallel partially nested randomized controlled feasibility trial with progression to full-scale trial. <i>Trials</i> , 2021, 22, 856.	1.6	4
40	New therapeutic approaches for ANCA-associated vasculitides. <i>Presse Medicale</i> , 2016, 45, e171-e178.	1.9	3
41	Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program. <i>Pilot and Feasibility Studies</i> , 2022, 8, 45.	1.2	3
42	<i>Listeria monocytogenes</i> pleuritis: Report of a geriatric case. <i>Geriatrics and Gerontology International</i> , 2013, 13, 505-506.	1.5	2
43	Primary biliary cholangitis and systemic sclerosis (Reynolds syndrome): A case-control study. <i>Autoimmunity Reviews</i> , 2021, 20, 102842.	5.8	2
44	Could a citrus keep the haematologist away?. <i>British Journal of Haematology</i> , 2014, 166, 298-300.	2.5	1
45	Organizing pneumonia and occupational and environmental risk factors: a case-control study. <i>International Archives of Occupational and Environmental Health</i> , 2017, 90, 865-871.	2.3	1
46	Digital Ischemia Induced by Fesoterodine. <i>Journal of Clinical Rheumatology</i> , 2021, 27, e212-e213.	0.9	1
47	Characteristics of patients with systemic sclerosis suffering from a lower limb amputation: Results of a French collaborative study. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 224-230.	1.7	1
48	Treatment of ANCA-Associated Vasculitides. <i>Rare Diseases of the Immune System</i> , 2020, , 313-328.	0.1	1
49	FRI0607...IDENTIFICATION OF UNMET NEEDS RELATED TO RARE AND COMPLEX CONNECTIVE TISSUE AND MUSCULOSKELETAL DISEASES (RCTDS) ACROSS EU: THE EXPERIENCE OF THE ERN RECONNET. , 2019, , .		0
50	Osteitis in Systemic Sclerosis: a nationwide case-control retrospective study (SCLEROS Study). <i>Arthritis Care and Research</i> , 2020, , .	3.4	0